NR4A1 and breast cancer: A randomized clinical trial of hormone-receptor negative BC patients has in fact already demonstrated a positive effect of inducing temporary ovarian insufficiency using goserelin (a gonadotropin-releasing hormone analogue that inhibits ovarian hormone production) on prognosis [24].